在临床相关模型中,用于缺血性心脏病的生物工程细胞和非细胞疗法
Kelsey C Muir1,2, Clark Zheng1,2, Keertana Yalamanchili2
1Department of Surgery, Division of Cardiothoracic Surgery, Warren Alpert Medical School, Providence, RI 02903, USA.
Bioengineering (Basel, Switzerland)
|January 28, 2026
概括
新型生物工程策略,如干细胞和细胞外囊泡,通过促进血管生长,显示出治疗缺血性心脏病 (IHD) 的前景. 大型动物模型对于将这些疗法推向临床应用至关重要.
科学领域:
- 心血管研究研究心血管研究
- 再生医学是一种再生医学.
- 生物医学工程 生物医学工程
背景情况:
- 缺血性心脏病 (IHD) 是全球主要的死亡和残疾原因.
- 心肌的再生能力有限,需要采取保护心脏组织的策略.
- 目前的治疗方法在临床转化方面面临挑战,原因是植入问题和安全问题.
研究的目的:
- 审查新兴的生物工程方法来治疗IHD.
- 评估细胞和非细胞治疗方式.
- 突出大型动物模型在翻译研究中的作用.
主要方法:
- 对细胞疗法 (干细胞/原生细胞) 的审查.
- 对非细胞疗法 (细胞外囊泡,生长因子,ECM支架) 的审查.
- 重点是大型动物模型和临床试验数据.
主要成果:
- 生物工程策略旨在增强心脏中的新血管化和结构修复.
- 干细胞,EV和矩阵支架显示出肌肉心脏恢复的潜力.
- 大型动物模型对于在人体试验之前评估疗效和安全至关重要.
结论:
- 尽管面临挑战,生物工程为IHD治疗提供了有前途的途径.
- 对转化模型的进一步研究对于临床成功至关重要.
- 优化移植,产品的一致性和安全性是未来疗法的关键.
相关概念视频
Ischemic Heart Disease: Overview
3.4K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
3.4K
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
570
The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
570
Clinically Relevant Drug Product Specifications: Methods of Establishment
215
Product specifications define the acceptable quality of a pharmaceutical product by ensuring identity, purity, potency, and strength. These specifications serve as benchmarks during development, manufacturing, and post-approval quality control. Clinically relevant specifications are particularly important because they directly relate to a drug's safety and efficacy in clinical use.Dissolution studies are critical biopharmaceutic tools that link in vitro behavior to in vivo performance. They...
215
Heart Failure VI: Adjunct Therapies
314
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
314
Heart Failure III: Clinical Manifestations
569
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
569
Rheumatic Heart Disease I: Introduction
510
Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
510


